MX2017016244A - Derivados de amidas policiclicas como inhibidores de cdk9. - Google Patents
Derivados de amidas policiclicas como inhibidores de cdk9.Info
- Publication number
- MX2017016244A MX2017016244A MX2017016244A MX2017016244A MX2017016244A MX 2017016244 A MX2017016244 A MX 2017016244A MX 2017016244 A MX2017016244 A MX 2017016244A MX 2017016244 A MX2017016244 A MX 2017016244A MX 2017016244 A MX2017016244 A MX 2017016244A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- cdk9
- derivatives
- amidas
- political
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polyesters Or Polycarbonates (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Detergent Compositions (AREA)
Abstract
Se provee una serie de derivados novedosos de piridina o pirimidina que inhiben CDK9 y pueden se útiles para el tratamiento de enfermedades hiperproliferativas. En particular, los compuestos son útiles en el tratamiento de enfermedades proliferativas como por ejemplo cáncer, incluyendo trastornos hematológicos malignos, como por ejemplo leucemia mieloide aguda, mieloma múltiple, leucemia linfocítica crónica, linfoma difuso de células B grandes, linfoma de Burkitt, linfoma folicular y tumores sólidos como por ejemplo cáncer de mama, cáncer de pulmón, neuroblastoma y cáncer de colon.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185852P | 2015-06-29 | 2015-06-29 | |
| PCT/EP2016/064899 WO2017001354A1 (en) | 2015-06-29 | 2016-06-27 | Polycyclic amide derivatives as cdk9 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017016244A true MX2017016244A (es) | 2018-04-20 |
| MX371034B MX371034B (es) | 2020-01-13 |
Family
ID=56292699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017016244A MX371034B (es) | 2015-06-29 | 2016-06-27 | Derivados de amidas policíclicas como inhibidores de cdk9. |
Country Status (38)
| Country | Link |
|---|---|
| US (4) | US9845331B2 (es) |
| EP (2) | EP3313838B1 (es) |
| JP (1) | JP6997627B2 (es) |
| KR (1) | KR102663113B1 (es) |
| CN (1) | CN107873028B (es) |
| AR (1) | AR105179A1 (es) |
| AU (1) | AU2016286200B2 (es) |
| BR (1) | BR122019013677B1 (es) |
| CA (1) | CA2989499C (es) |
| CL (1) | CL2017003306A1 (es) |
| CO (1) | CO2017013713A2 (es) |
| CR (2) | CR20210297A (es) |
| CY (2) | CY1122111T1 (es) |
| DK (2) | DK3539961T3 (es) |
| DO (2) | DOP2017000295A (es) |
| EA (1) | EA035383B1 (es) |
| ES (2) | ES2728356T3 (es) |
| HR (2) | HRP20190748T1 (es) |
| HU (2) | HUE043440T2 (es) |
| IL (1) | IL256393B (es) |
| LT (2) | LT3539961T (es) |
| ME (1) | ME03404B (es) |
| MX (1) | MX371034B (es) |
| MY (1) | MY201673A (es) |
| NI (1) | NI201700174A (es) |
| PE (1) | PE20180530A1 (es) |
| PH (1) | PH12017502334B1 (es) |
| PL (2) | PL3313838T3 (es) |
| PT (2) | PT3313838T (es) |
| RS (2) | RS58712B1 (es) |
| SI (2) | SI3539961T1 (es) |
| SM (2) | SMT201900298T1 (es) |
| SV (1) | SV2017005598A (es) |
| TN (1) | TN2017000486A1 (es) |
| TR (1) | TR201909286T4 (es) |
| TW (1) | TWI723028B (es) |
| WO (1) | WO2017001354A1 (es) |
| ZA (1) | ZA201800563B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3075952A1 (en) | 2017-09-25 | 2019-03-28 | Astrazeneca Ab | Combination of a btk inhibitor and an inhibitor of cdk9 to treat cancer |
| US11319295B2 (en) | 2017-10-09 | 2022-05-03 | Merck Sharp & Dohme Corp. | Substituted phenyloxetane and phenyltetrahydrofuran compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
| CN108129288B (zh) * | 2017-12-27 | 2021-01-22 | 上海毕得医药科技股份有限公司 | 一种反式-3-羟基环丁基甲酸的合成方法 |
| TW202344250A (zh) | 2018-11-14 | 2023-11-16 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| CN114008046B (zh) * | 2019-06-27 | 2023-08-18 | 南京明德新药研发有限公司 | 作为cdk9抑制剂的氮杂吲哚连吡唑类化合物 |
| CA3153531A1 (en) | 2019-09-11 | 2021-03-18 | Prelude Therapeutics Incorporated | Cdk inhibitors and their use as pharmaceuticals |
| CN114787142B (zh) * | 2019-12-09 | 2024-08-02 | 石药集团中奇制药技术（石家庄）有限公司 | 作为周期蛋白依赖性激酶9抑制剂的化合物及其应用 |
| WO2021227906A1 (zh) * | 2020-05-12 | 2021-11-18 | 苏州阿尔脉生物科技有限公司 | 一种作为cdk抑制剂的吡啶乙酰胺类衍生物、其制备方法及用途 |
| EP4141004A4 (en) * | 2020-05-12 | 2023-08-23 | Suzhou Alphama Biotechnology Co., Ltd. | POLYCYCLIC AMIDE DERIVATIVE SERVING AS A CDK9 INHIBITOR, METHOD FOR PREPARING IT AND ITS USE |
| JP7794766B2 (ja) * | 2020-06-24 | 2026-01-06 | アストラゼネカ ユーケー リミテッド | 抗体－薬物複合物及びｃｄｋ９阻害剤の組み合わせ |
| JP7537002B2 (ja) | 2020-08-07 | 2024-08-20 | 南京薬石科技股▲フン▼有限公司 | Ｃｄｋ９阻害剤およびその使用 |
| TWI809330B (zh) * | 2020-11-20 | 2023-07-21 | 大陸商勁方醫藥科技(上海)有限公司 | Cdk9抑制劑的多晶型物及其製法和用途 |
| WO2022247785A1 (zh) * | 2021-05-24 | 2022-12-01 | 石药集团中奇制药技术（石家庄）有限公司 | 一种周期蛋白依赖性激酶9抑制剂的用途 |
| CN115381824B (zh) * | 2021-05-24 | 2024-11-05 | 石药集团中奇制药技术（石家庄）有限公司 | 周期蛋白依赖性激酶9抑制剂的用途 |
| CN117813289A (zh) * | 2021-07-14 | 2024-04-02 | 上海海雁医药科技有限公司 | 吡唑衍生物及其中间体和制备方法 |
| CN115703738B (zh) * | 2021-08-16 | 2024-06-21 | 中国科学院上海药物研究所 | 含2-芳杂环取代的脲类化合物、其制备方法和用途 |
| CN118613257A (zh) * | 2021-12-23 | 2024-09-06 | 鲁汶大学 | 用于抑制yap/taz-tead的四氢吡唑并嘧啶及相关类似物 |
| AU2023326499A1 (en) | 2022-08-17 | 2025-03-27 | Korea Research Institute Of Bioscience And Biotechnology | Compounds for inhibiting or decomposing cdk2 and/or cdk9, and medicinal uses thereof |
| CN117659022A (zh) * | 2022-09-06 | 2024-03-08 | 苏州阿尔脉生物科技有限公司 | 脲基取代吡啶类化合物、包含其的药物组合物及其医药用途 |
| US20240360075A1 (en) * | 2023-04-19 | 2024-10-31 | Alcon Inc. | N-substituted c6 cyclyl carboxamide compounds and uses thereof |
| WO2025076115A1 (en) * | 2023-10-02 | 2025-04-10 | Prelude Therapeutics Incorporated | Cdk inhibitors and their use as pharmaceuticals |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008133192A1 (ja) | 2007-04-19 | 2008-11-06 | Takeda Pharmaceutical Company Limited | 縮合イミダゾール化合物およびその用途 |
| EP2137166B1 (en) | 2007-04-24 | 2012-05-30 | Ingenium Pharmaceuticals GmbH | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases |
| WO2008129071A1 (en) | 2007-04-24 | 2008-10-30 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| ES2539518T3 (es) | 2007-04-24 | 2015-07-01 | Astrazeneca Ab | Inhibidores de proteínas quinasas |
| WO2008129069A1 (en) | 2007-04-24 | 2008-10-30 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| WO2008132138A1 (en) | 2007-04-25 | 2008-11-06 | Ingenium Pharmaceuticals Gmbh | Derivatives of 4,6-disubstituted aminopyrimidines |
| BRPI0818543A2 (pt) | 2007-10-12 | 2018-10-23 | Ingenium Pharmaceuticals Gmbh | inibidores de proteína cinase |
| KR20120049940A (ko) | 2009-09-04 | 2012-05-17 | 노파르티스 아게 | 키나제 억제제로서의 헤테로아릴 화합물 |
| US20110113038A1 (en) | 2009-11-12 | 2011-05-12 | International Business Machines Corporation | Search term security |
| GB201002911D0 (en) | 2010-02-19 | 2010-04-07 | Medical Res Council | Compound |
| KR20130016244A (ko) | 2010-03-10 | 2013-02-14 | 인게니움 파르마코이티칼스 게엠베하 | 단백질 키나아제의 억제제 |
| AR081810A1 (es) | 2010-04-07 | 2012-10-24 | Bayer Cropscience Ag | Piridinilpirazoles biciclicos |
| WO2012066065A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | Phenyl-heteroaryl amine compounds and their uses |
| EP2668162A1 (en) * | 2011-01-28 | 2013-12-04 | Novartis AG | Substituted bi-heteroaryl compounds as cdk9 inhibitors and their uses |
| WO2012101064A1 (en) * | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyrimidine biaryl compounds as protein kinase inhibitors |
| WO2012101063A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyridine biaryl compounds and their uses |
| KR20140072177A (ko) | 2011-10-06 | 2014-06-12 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 헤테로사이클릴피리(미)디닐피라졸 |
| MX2015012432A (es) * | 2013-03-13 | 2016-02-05 | Abbvie Inc | Inhibidores piridinicos de la cinasa cdk9. |
| BR112015023013A2 (pt) | 2013-03-13 | 2017-07-18 | Abbvie Inc | inibidores de quinase cdk9 |
| BR112015023078A2 (pt) | 2013-03-14 | 2017-07-18 | Abbvie Inc | inibidores de pirrolopirimindina cdk9 quinase |
| TW201446763A (zh) | 2013-03-14 | 2014-12-16 | Abbvie Inc | 吡咯并［２，３－ｂ］吡啶ｃｄｋ９激酶抑制劑 |
-
2016
- 2016-06-27 MY MYPI2017705054A patent/MY201673A/en unknown
- 2016-06-27 HU HUE16733459A patent/HUE043440T2/hu unknown
- 2016-06-27 PL PL16733459T patent/PL3313838T3/pl unknown
- 2016-06-27 CA CA2989499A patent/CA2989499C/en active Active
- 2016-06-27 SI SI201631427T patent/SI3539961T1/sl unknown
- 2016-06-27 EP EP16733459.8A patent/EP3313838B1/en active Active
- 2016-06-27 BR BR122019013677-7A patent/BR122019013677B1/pt active IP Right Grant
- 2016-06-27 TR TR2019/09286T patent/TR201909286T4/tr unknown
- 2016-06-27 AU AU2016286200A patent/AU2016286200B2/en active Active
- 2016-06-27 RS RS20190564A patent/RS58712B1/sr unknown
- 2016-06-27 CR CR20210297A patent/CR20210297A/es unknown
- 2016-06-27 CR CR20170596A patent/CR20170596A/es unknown
- 2016-06-27 LT LTEP19165726.1T patent/LT3539961T/lt unknown
- 2016-06-27 ES ES16733459T patent/ES2728356T3/es active Active
- 2016-06-27 PE PE2017002874A patent/PE20180530A1/es unknown
- 2016-06-27 RS RS20220005A patent/RS62781B1/sr unknown
- 2016-06-27 EP EP19165726.1A patent/EP3539961B1/en active Active
- 2016-06-27 WO PCT/EP2016/064899 patent/WO2017001354A1/en not_active Ceased
- 2016-06-27 ES ES19165726T patent/ES2902148T3/es active Active
- 2016-06-27 SI SI201630247T patent/SI3313838T1/sl unknown
- 2016-06-27 PH PH1/2017/502334A patent/PH12017502334B1/en unknown
- 2016-06-27 DK DK19165726.1T patent/DK3539961T3/da active
- 2016-06-27 TN TNP/2017/000486A patent/TN2017000486A1/en unknown
- 2016-06-27 KR KR1020187002262A patent/KR102663113B1/ko active Active
- 2016-06-27 ME MEP-2019-138A patent/ME03404B/me unknown
- 2016-06-27 LT LTEP16733459.8T patent/LT3313838T/lt unknown
- 2016-06-27 PT PT16733459T patent/PT3313838T/pt unknown
- 2016-06-27 MX MX2017016244A patent/MX371034B/es active IP Right Grant
- 2016-06-27 PT PT191657261T patent/PT3539961T/pt unknown
- 2016-06-27 SM SM20190298T patent/SMT201900298T1/it unknown
- 2016-06-27 DK DK16733459.8T patent/DK3313838T3/da active
- 2016-06-27 US US15/193,826 patent/US9845331B2/en active Active
- 2016-06-27 JP JP2017567737A patent/JP6997627B2/ja active Active
- 2016-06-27 CN CN201680029447.9A patent/CN107873028B/zh active Active
- 2016-06-27 HR HRP20190748TT patent/HRP20190748T1/hr unknown
- 2016-06-27 PL PL19165726T patent/PL3539961T3/pl unknown
- 2016-06-27 EA EA201890094A patent/EA035383B1/ru not_active IP Right Cessation
- 2016-06-27 HU HUE19165726A patent/HUE057343T2/hu unknown
- 2016-06-27 SM SM20220005T patent/SMT202200005T1/it unknown
- 2016-06-27 HR HRP20211970TT patent/HRP20211970T1/hr unknown
- 2016-06-28 AR ARP160101956A patent/AR105179A1/es unknown
- 2016-06-28 TW TW105120362A patent/TWI723028B/zh active
-
2017
- 2017-12-06 US US15/833,277 patent/US10717746B2/en active Active
- 2017-12-12 DO DO2017000295A patent/DOP2017000295A/es unknown
- 2017-12-18 IL IL256393A patent/IL256393B/en unknown
- 2017-12-20 SV SV2017005598A patent/SV2017005598A/es unknown
- 2017-12-21 CL CL2017003306A patent/CL2017003306A1/es unknown
- 2017-12-22 NI NI201700174A patent/NI201700174A/es unknown
- 2017-12-28 CO CONC2017/0013713A patent/CO2017013713A2/es unknown
-
2018
- 2018-01-26 ZA ZA2018/00563A patent/ZA201800563B/en unknown
- 2018-09-25 DO DO2018000207A patent/DOP2018000207A/es unknown
-
2019
- 2019-06-19 CY CY20191100636T patent/CY1122111T1/el unknown
-
2020
- 2020-07-17 US US16/931,786 patent/US11352369B2/en active Active
-
2021
- 2021-12-22 CY CY20211101125T patent/CY1125066T1/el unknown
-
2022
- 2022-04-27 US US17/660,935 patent/US20220340592A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2018000207A (es) | Derivados de amidas policíclicas como inhibidores de cdk9 | |
| AR123996A2 (es) | Compuestos tricíclicos novedosos como agentes antineoplásicos | |
| CL2018003316A1 (es) | Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786) | |
| CY1123938T1 (el) | Συνδυασμος αντισωματος αντι-cd20 και εκλεκτικου αναστολεα κινασης p13 | |
| CL2018001591A1 (es) | Compuestos útiles como inhibidores de cinasa.- | |
| ECSP17072987A (es) | Compuestos nucleósidos 5-sustituidos | |
| DOP2018000278A (es) | Compuestos de 2,3-dihidro-1h-indol | |
| CY1122478T1 (el) | Συνθεσεις που περιεχουν anti-cd38 αντισωματα και λεναλιδομιδη | |
| CL2019000542A1 (es) | Compuestos de tetraciclina y métodos de uso de los mismos. | |
| NI201800042A (es) | Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1 | |
| NI201700071A (es) | Anticuerpos anti-cd38 para el tratamiento de la leucemia mieloide aguda | |
| MX2016001963A (es) | Metodo de seleccion. | |
| MX2016013863A (es) | Combinacion de lenalidomida y constructo de polipeptido, y sus usos. | |
| MD3395820T2 (ro) | Compuși antitumorali | |
| CL2017001511A1 (es) | Derivados de piperidina como inhibidores de hdac1/2. | |
| CR20170111A (es) | Derivados de benzodiazepina citotóxicos | |
| CL2016001368A1 (es) | Inhibidores de cinasa serina/treonina | |
| BR112015024558A2 (pt) | método para tratamento de leucemia mieloide. | |
| BR112019003130A2 (pt) | agonista de ppargama para tratamento de cânceres de sangue | |
| IL261160B (en) | Methods of treating acute myeloid leukemia | |
| MX385940B (es) | Nuevos antiestrógenos heterocíclicos. | |
| SG11202112061RA (en) | Bisfluoroalkyl-1,4-benzodiazepin one compounds for treating notch-activated breast cancer | |
| IL282853A (en) | Feeding unit for a gemstone machine | |
| EA201992557A1 (ru) | Противоопухолевые соединения | |
| AR109273A1 (es) | Usos de compuestos de indolina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |